Trimipramine
Brand names: Surmontil
Trimipramine is a tricyclic antidepressant used in the treatment of depression, particularly where sedation is desirable.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits reuptake of noradrenaline and serotonin and has marked antagonism at histamine H1, muscarinic and alpha-adrenergic receptors, accounting for its sedative and antimuscarinic profile.
Prescribing in practice
- Tricyclic antidepressants are dangerous in overdose, causing cardiac arrhythmias, seizures and coma, so the risk should be assessed in patients at risk of self-harm.
- Antimuscarinic effects and postural hypotension are common, warranting caution in cardiac disease, glaucoma, prostatic hypertrophy and the elderly.
- It lowers the seizure threshold and should be used with caution in epilepsy, avoiding abrupt withdrawal.
Monitoring
Monitor mood and suicidal ideation, cardiovascular status and antimuscarinic side effects, particularly when initiating or adjusting treatment.
Counselling the patient
- This medicine is sedating and may cause drowsiness; avoid driving until you know how it affects you.
- Dry mouth, blurred vision and constipation are common, especially at first.
- It can be very dangerous in overdose, so take only as prescribed and seek advice before stopping.
Evidence & guidelines
The overdose toxicity of tricyclic antidepressants such as trimipramine is well documented and reflected in NICE depression guidance.
Reference: NICE NG222; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185